首页> 外文期刊>Antimicrobial agents and chemotherapy. >Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic
【24h】

Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic

机译:药物动力学增强的阿莫西林-克拉维酸盐每天两次2,000 / 125毫克连续5天的疗效和安全性,而阿莫西林-克拉维酸盐每天875/125毫克每天两次两次,连续7天的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

This randomized, controlled trial was designed to show that a short, 5-day course of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 mg (Augmentin XR) is as effective clinically as a longer, 7-day course of conventional amoxicillin-clavulanate at 875/125 mg (both given twice daily) in the treatment of acute exacerbations of chronic bronchitis (AECB). Amoxicillin-clavulanate at 2,000/125 mg was designed to extend the therapeutic levels of amoxicillin in serum over the 12-h dosing interval, compared with conventional formulations, to eradicate bacterial strains for which amoxicillin MICs were
机译:这项随机对照试验旨在证明,在2,000 / 125 mg(Augmentin XR)上药代动力学增强的阿莫西林-克拉维酸盐短期5天疗程与常规阿莫西林-克拉维酸盐7天较长疗程在临床上一样有效875/125毫克(每天两次),用于治疗慢性支气管炎(AECB)的急性加重。与常规制剂相比,阿莫西林-克拉维酸2,000 / 125 mg的设计用于在12小时给药间隔内将血清中阿莫西林的治疗水平延长,以根除阿莫西林MIC≤= 4杯/ ml的细菌菌株,同时保留对抗产生β-内酰胺酶的病原体的功效。总共893例患者被随机分配并接受研究用药(阿莫西林-克拉维酸盐2,000 / 125 mg,443例,875/125 mg,450例)。总体上,有141例接受2,000 / 125 mg阿莫西林-克拉维酸盐治疗的患者和135例接受了比较制剂的患者在筛选时至少鉴定出一种病原体。 2,000 / 125 mg阿莫西林-克拉维酸盐在临床试验(第14至21天,主要功效终点)的按方案(PP)人群中的临床疗效与875/125 mg阿莫西林-克拉维酸盐(临床成功率分别为93.0%和91.2%;治疗差异为1.8; 95%置信区间[CI],-2.2,5.7)。两种制剂在细菌学PP人群中的细菌学成功率均很高(阿莫西林-克拉维酸盐为2,000 / 125 mg,占76.7%;阿莫西林-克拉维酸盐为875/125 mg,占73.0%;治疗差异为3.8; 95%CI,-7.5,15.0 )。两种疗法的耐受性良好,不良事件的发生率相似。由于不良事件,每组中只有不到5%的患者退出研究。在2000/125 mg的阿莫西林-克拉维酸盐较短的5天疗程中,与在875/125 mg的阿莫西林-克拉维酸盐7天的较长疗程一样,在临床上被证明是有效的,并且具有较高的细菌学功效并且耐受性没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号